Amneal Pharmaceuticals (NYSE:AMRX) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.
A number of other research firms have also weighed in on AMRX. Guggenheim initiated coverage on shares of Amneal Pharmaceuticals in a report on Thursday, September 12th. They issued a “sell” rating and a $2.50 target price for the company. Svb Leerink lowered shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lowered shares of Amneal Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday. BMO Capital Markets cut their target price on shares of Amneal Pharmaceuticals from $5.00 to $4.00 and set a “market perform” rating for the company in a report on Monday. Finally, Leerink Swann lowered shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. Amneal Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.50.
Shares of AMRX opened at $2.70 on Wednesday. The company has a debt-to-equity ratio of 6.91, a current ratio of 2.25 and a quick ratio of 1.50. Amneal Pharmaceuticals has a 1 year low of $2.27 and a 1 year high of $20.40. The company has a 50 day simple moving average of $3.06 and a two-hundred day simple moving average of $5.24. The firm has a market cap of $816.52 million, a P/E ratio of 2.84, a price-to-earnings-growth ratio of 1.53 and a beta of 1.48.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.09). Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. The business had revenue of $378.30 million during the quarter, compared to analysts’ expectations of $403.90 million. During the same period last year, the business posted $0.28 earnings per share. The company’s revenue for the quarter was down 20.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.45 earnings per share for the current year.
In other news, SVP Pradeep Bhadauria acquired 30,000 shares of the company’s stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $2.41 per share, with a total value of $72,300.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ted C. Nark acquired 50,000 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were purchased at an average cost of $2.39 per share, with a total value of $119,500.00. The disclosure for this purchase can be found here. 25.92% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its stake in Amneal Pharmaceuticals by 2.1% during the second quarter. Swiss National Bank now owns 171,200 shares of the company’s stock worth $1,228,000 after buying an additional 3,600 shares during the period. Atria Investments LLC purchased a new position in Amneal Pharmaceuticals during the second quarter worth $240,000. Assenagon Asset Management S.A. purchased a new position in Amneal Pharmaceuticals during the third quarter worth $971,000. Point72 Asset Management L.P. purchased a new position in Amneal Pharmaceuticals during the second quarter worth $23,772,000. Finally, Acadian Asset Management LLC boosted its stake in Amneal Pharmaceuticals by 96.3% during the second quarter. Acadian Asset Management LLC now owns 45,000 shares of the company’s stock worth $323,000 after buying an additional 22,073 shares during the period. 34.96% of the stock is owned by institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.